Eli Lilly and’s (LLY) Sell Rating Reiterated at BMO Capital Markets
Eli Lilly and Company (NYSE:LLY)‘s stock had its “sell” rating reissued by stock analysts at BMO Capital Markets in a report released on Wednesday. They currently have a $73.00 price objective on the stock. BMO Capital Markets’ price objective indicates a potential downside of 9.53% from the company’s current price.
Other research analysts have also issued research reports about the stock. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Jefferies Group LLC restated a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a report on Thursday, June 22nd. Citigroup Inc. raised their price target on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, April 19th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a report on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $88.27.
Shares of Eli Lilly and (LLY) traded down 1.25% on Wednesday, hitting $80.69. 3,942,489 shares of the company were exchanged. The company has a 50-day moving average price of $82.77 and a 200 day moving average price of $81.92. Eli Lilly and has a 52-week low of $64.18 and a 52-week high of $86.72. The firm has a market cap of $85.13 billion, a P/E ratio of 34.92 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the firm posted $0.86 earnings per share. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. Analysts predict that Eli Lilly and will post $4.16 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/16/eli-lilly-ands-lly-sell-rating-reiterated-at-bmo-capital-markets-2.html.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock valued at $55,845,287 in the last three months. Corporate insiders own 0.20% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Keel Point LLC increased its position in Eli Lilly and by 2.6% in the second quarter. Keel Point LLC now owns 7,765 shares of the company’s stock worth $639,000 after buying an additional 200 shares in the last quarter. Verition Fund Management LLC increased its position in Eli Lilly and by 38.6% in the second quarter. Verition Fund Management LLC now owns 7,133 shares of the company’s stock worth $587,000 after buying an additional 1,987 shares in the last quarter. Westwood Holdings Group Inc. acquired a new position in Eli Lilly and during the second quarter worth approximately $215,000. BB&T Investment Services Inc. acquired a new position in Eli Lilly and during the second quarter worth approximately $577,000. Finally, Intellectus Partners LLC increased its position in Eli Lilly and by 5.1% in the second quarter. Intellectus Partners LLC now owns 4,458 shares of the company’s stock worth $367,000 after buying an additional 216 shares in the last quarter. 75.59% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.